AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019

May 20, 2019

MENLO PARK, Calif.--(BUSINESS WIRE)--May 20, 2019--

Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21 st at 11:00 AM BST.

The  presentation, entitled “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT ™. In addition to an overview, the presentation will introduce preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy.

ImmunoID NeXT™  is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the biological information that can be generated from a precious tumor specimen.

The presentation will be delivered by Robert Power, MS, Global Product Manager for Personalis.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform™ is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. The Personalis  Clinical Laboratory is GxP-aligned as well as CLIA ’88-certified and CAP-accredited. For more information, please visit  www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ).

View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005195/en/

CONTACT: Jennifer Havlek

pr@personalis.com

www.personalis.com

650-752-1300

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY PHARMACEUTICAL

SOURCE: Personalis, Inc.

Copyright Business Wire 2019.

PUB: 05/20/2019 03:05 AM/DISC: 05/20/2019 03:05 AM

http://www.businesswire.com/news/home/20190520005195/en

All contents © copyright 2019 The Associated Press.All rights reserved.